GLP-1 medications, like Ozempic, have become popular for their ability to support long-term weight loss when used under proper medical supervision
Semaglutide is one of the best-known GLP-1 medications used for chronic weight management under the brand name Wegovy
Concerns have arisen regarding compounded versions of GLP-1 drugs, with the FDA receiving over 700 adverse event reports due to dosing errors or unapproved formulations
This would make it the third major incretin-based obesity drug to reach the market, following semaglutide (Wegovy) and tirzepatide (Zepbound), but the first to use the full triple-agonist mechanism
USE IN PATIENTS WITH RENAL IMPAIRMENT Two trials are available examining the impact of renal impairment on oral semaglutide safety, tolerability, and pharmacokinetics
This is based on its 6 to 8 day half-life and the pharmacological principle that 4 to 5 half-lives are required for near-complete elimination